BridgeBio Pharma, Inc. (BBIO) earnings date

Nasdaq · Large cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 36 days, typically, give or take 10 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Thu, Oct 29, 2026after close 29 8-K
Q2 FY2026Mon, Aug 10, 2026after close 41 8-K
Q1 FY2026Thu, May 7, 2026after close 37 8-K
Q4 FY2025Tue, Feb 24, 2026after close 55 8-K
Q3 FY2025Wed, Oct 29, 2025after close 29 8-K
Q2 FY2025Tue, Aug 5, 2025after close 36 8-K
Q1 FY2025Tue, Apr 29, 2025after close 29 8-K
Q4 FY2024Thu, Feb 20, 2025before open 51 8-K

What they guided beta

Q3 FY2026 "Cash, cash equivalents and marketable securities were $1.5 billion as of September 30, 2026, fully funding all three launches and expansion indications - Attruby growth was again led by the treatment-naïve segment, with both the number of newly diagnosed patients starting treatment and Attruby's share of those starts increasing - Real-world evidence continues to differentiate acoramidis from tafamidis on outcomes that matter to patients, physicians, and payers: (i) an independent Epic COSMOS analysis of 2,684 patients found an 18% lower risk of death, hospitalization, new atrial fibrillation o" exhibit
Q3 FY2026 "Topline data are expected in early 2028, representing a potential second indication in an estimated population of 200,000 patients in the U.S. and EU PALO ALTO, Calif., October 29, 2026 -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today its financial results for the third quarter ended September 30, 2026, and provided an update on Attruby’s commercial progress. 1 Pipeline Overview: Program Status Next expected milestone Acoramidis for ATTR-CM" exhibit
Q3 FY2026 "Additional data on the benefit of acoramidis for individuals with ATTR-CM will be shared at the upcoming American Heart Association (AHA) 2026 Scientific Sessions." exhibit
Q3 FY2026 "Since entering the field in August 2026, the Company’s Neuromuscular Account Managers have reached more than 70% of MDA centers and are expected to reach at least 90% of these centers by the PDUFA date." exhibit
Q3 FY2026 "The MAA will be based on the final analysis of the Phase 3 FORTIFY study at Month 36, with topline results expected late 2027/early 2028." exhibit
Q2 FY2026 "Document Exhibit 99.1 BridgeBio Reports Second Quarter 2026 Financial Results and Corporate Updates - $243.7 million in total second quarter revenues, primarily comprised of $222.4 million of U.S. Attruby® net product revenue, with growth led by the treatment-naïve segment as physicians increasingly start and keep patients on Attruby - Attruby is the first ATTR-CM therapy associated with direct kidney protection, with post-hoc analyses published in Circulation: Heart Failure showing a profile consistent with ACE inhibitors, ARBs, and SGLT2s including an early, reversible eGFR dip, an improved " exhibit
Q2 FY2026 "Additional data will be shared in two oral presentations and six moderated posters at the European Society of Cardiology (ESC) Congress 2026." exhibit
Q2 FY2026 "The Company submitted an NDA to the FDA for oral infigratinib in achondroplasia and is on track to submit an MAA to the EMA in the fourth quarter of 2026." exhibit
Q2 FY2026 "BridgeBio anticipates a U.S. launch in mid-2027 and an EU approval in the second half of 2027." exhibit
Q2 FY2026 "An update of the Phase 2 program in hypochondroplasia is expected in the second half of 2026." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/BBIO
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/BBIO

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

BBIO earnings date badge

HTML

<a href="https://veritasdata.dev/company/BBIO/"><img src="https://veritasdata.dev/embed/BBIO.svg" alt="BBIO earnings date" width="240" height="56"></a>

Markdown

[![BBIO earnings date](https://veritasdata.dev/embed/BBIO.svg)](https://veritasdata.dev/company/BBIO/)

Script

<script async src="https://veritasdata.dev/embed/BBIO.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/BBIO"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.